



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

**2009 Annual Report and
Notice of Annual General Meeting**

London: Monday, 29 March 2010: Chi-Med today announces that its 2009 Annual Report together with the Notice of Annual General Meeting and the Proxy Form have been posted to shareholders. The documents can be accessed from the website of Chi-Med (www.chi-med.com).

Ends

Enquiries

Chi-Med
Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson
Anthony Carlisle
David Dible

Telephone: +44 (0) 20 7638 9571
+44 (0) 7973 611 888
+44 (0) 7967 566 919

Lazard & Co., Ltd.
Paul Gismondi
Nick Fowler

Telephone: +44 (0) 20 7187 2000

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.